GlaxoSmithKline Lamictal Recall Lawsuit
GlaxoSmithKline Recall of Lamictal 200mg Tablets
Pharmaceutical company GlaxoSmithKline has recalled two batches of Lamictal (lamotrigine) 200mg tablets after an issue related to delayed dissolution is discovered. The Medicines and Healthcare Products Regulatory Agency of the United Kingdom has issued a Class 2 drug alert on the matter, which necessitates action for pharmacy level recall within 48 hours.
The delayed dissolution of the Lamictal 200mg tablet is unlikely to impact plasma concentrations in patients who have already taken tablets from these batches. However, there is still risk that some of the patients experience a reduction in efficacy after receiving these particular tablets. The risk is pegged at very low and the numbers of such patients are also expected to be small.
The issue is only limited to Lamictal 200mg tablets of GlaxoSmithKline with the batch numbers PJ1925 and PJ1926. These are in distribution since November 2010 and expiry date mentioned on them is August 31, 2013. No other batch of the GlaxoSmithKline-made Lamictal 200mg tablets, dose forms, and the overall strength of Lamictal drug stand affected by this issue.